The Cologne, Germany-based cancer diagnostics firm plans to use the funds raised to develop a liquid biopsy for its NGS-based NEO platform.
AmoyDx will develop and commercialize a series of oncology tests that use Illumina NGS technology, including the firm's TruSight Tumor 15 panel.
Under the terms of the agreement, N-of-One will provide clinical interpretation services for samples sequenced on a 50-gene hot-spot solid tumor panel.
CiViC provides a communal forum for capturing and sharing written summaries, drawn from published literature, about the clinical relevance of mutations found in cancer.
Deck: The panels, which cover lung, colon, brain, and thyroid cancer as well as melanoma and gastrointestinal stromal tumors, target newly diagnosed patients.
Mutations present in tissue from Barrett's esophagus may help predict progression to high-grade dysplasia or cancer.
The software provides clinical testing laboratories with tools, peer-reviewed content, and guidelines to interpret and report on variants found in oncology-based NGS tests.
Researchers presenting at ASCO demonstrated the 100-gene panel test plus targeted therapy leads to better outcomes and lower cost than standard chemotherapy.
Over the next two years, Cancer Genetics' genomic laboratory in Hyderabad, India, expects to analyze several thousand samples provided by ReproCell.
The company reported $1.2 million in revenues compared to $118,000 in the year-ago quarter.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.